abrdn Life Sciences Investors (NYSE:HQL) Hits New 12-Month High – What’s Next?

abrdn Life Sciences Investors (NYSE:HQL) shares hit a new 52-week high during trading on Monday . The stock traded as high as $20.20 and last traded at $20.2490, with a volume of 127466 shares. The stock had previously closed at $20.12.

abrdn Life Sciences Investors Stock Performance

The business’s fifty day moving average price is $17.88 and its two-hundred day moving average price is $17.22.

abrdn Life Sciences Investors Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, June 30th. Shareholders of record on Thursday, May 21st were given a dividend of $0.56 per share. This represents a $2.24 annualized dividend and a yield of 11.2%. The ex-dividend date of this dividend was Thursday, May 21st.

Institutional Trading of abrdn Life Sciences Investors

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. KPP Advisory Services LLC increased its holdings in shares of abrdn Life Sciences Investors by 5.8% during the 1st quarter. KPP Advisory Services LLC now owns 24,591 shares of the company’s stock valued at $400,000 after acquiring an additional 1,354 shares during the last quarter. Geneos Wealth Management Inc. lifted its holdings in abrdn Life Sciences Investors by 200.1% in the 2nd quarter. Geneos Wealth Management Inc. now owns 2,293 shares of the company’s stock worth $29,000 after purchasing an additional 1,529 shares during the last quarter. NewEdge Advisors LLC lifted its holdings in abrdn Life Sciences Investors by 5.2% in the 2nd quarter. NewEdge Advisors LLC now owns 34,190 shares of the company’s stock worth $438,000 after purchasing an additional 1,690 shares during the last quarter. Uhlmann Price Securities LLC boosted its position in abrdn Life Sciences Investors by 2.3% during the first quarter. Uhlmann Price Securities LLC now owns 77,857 shares of the company’s stock worth $1,267,000 after purchasing an additional 1,719 shares during the period. Finally, First Trust Advisors LP boosted its position in abrdn Life Sciences Investors by 4.0% during the fourth quarter. First Trust Advisors LP now owns 48,770 shares of the company’s stock worth $818,000 after purchasing an additional 1,880 shares during the period. Institutional investors and hedge funds own 32.21% of the company’s stock.

abrdn Life Sciences Investors Company Profile

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.